The 44th Annual Macula Society Meeting will be virtual from February 6 to 7 in 2021. Click Here to View the 2021 Virtual Conference Program. 

GS030, GenSight’s gene therapy product candidate to treat Retinitis Pigmentosa (RP), will be presented in the Paper Session – On Demand.

GS030 – Optogenetics in Retinitis Pigmentosa

Paper Title:  Optogenetic GS030 Therapy in Subjects with Retinitis Pigmentosa: Safety and Tolerability Up to Two Years After Treatment Administration in the Phase 1/2a PIONEER Study

Presenting AuthorJose Alain Sahel, MD, Chairman, University of Pittsburgh Medical Center, Pittsburgh, United States

Paper sessionInherited Retinal Disease – On-Demand